415963-48-3

Upstream product

• 374537-95-8 methyl 3-[4-(chlorosulfonyl)-phenyl]propanoate 
• 106-47-8 4-chloro-aniline 

Downstream Products

• 415963-51-8 3-{4-[(4-chloro-phenyl)-hydrazinocarbonylmethyl-sulfamoyl]-phenyl}-N-(3-dimethylamino-propyl)-propionamide 
• 415963-50-7 ((4-chloro-phenyl)-{4-[2-(3-dimethylamino-propylcarbamoyl)-ethyl]-benzenesulfonyl}-amino)-acetic acid methyl ester 
• 415963-49-4 3-{4-[(4-chloroanilino)sulfonyl]phenyl}-N-[3-(dimethylamino)propyl]propanamide 
• 904693-21-6 4-[3-(tert-butyl-dimethyl-silanyloxy)-propyl]-N-(4-chloro-phenyl)-benzenesulfonamide 

Relevant academic research and scientific papers

Discovery and development of a new class of potent, selective, orally active oxytocin receptor antagonists

We report a novel chemical class of potent oxytocin receptor antagonists showing a high degree of selectivity against the closely related vasopressin receptors (Via, V1b, V2). An initial compound, 7, was shown to be active in an animal model of preterm labor when administered by the intravenous but not by the oral route. Stepwise SAR investigations around the different structural elements revealed one position, the arenesulfonyl moiety, to be amenable to structural changes. Consequently, this position was used to introduce a variety of substituents to improve the physicochemical properties. Some of the resulting analogues were found to be superior to 7 both in terms of potency in vitro and aqueous solubility, which translated into significantly improved efficacy in the animal model after intravenous and oral administration. The best compound, 73, potently inhibited oxytocin-induced uterine contractions in nonpregnant rats and reduced spontaneous uterine contractions in late-term pregnant rats.

Pharmaceutically active sulfanilide derivatives

The present invention relates to sulfanilide derivatives of formula (I), in which R1 and R2 are optionally substituted aryl and heteroaryl groups and the other variables are as defined in the claims, for use as pharmaceutically active compounds, as well as pharmaceutical formulations containing such sulfanilide derivatives. Said derivatives are useful in the treatment and/or prevention of preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. In particular, the present invention is related to sulfanilide derivatives displaying a substantial modulatory, in particular antagonistic activity, of the oxytocin and/or vasopressin receptor. More preferably, said compounds are useful in the treatment and/or prevention of disease states mediated by oxytocin and/or vasopressin, including preterm labor, premature birth, dysmenorrhea, inappropriate secretion of vasopressin, congestive heart failure, arterial hypertension, liver cirrhosis, nephrotic syndrome and ocular hypertension. The present invention is furthermore related to novel sulfanilide derivatives as well as to methods of their preparation.